Evidence map›Paper›PMID 24982170›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Engineered nanomedicine for myeloma and bone microenvironment targeting.

Archana Swami, Michaela R Reagan, Pamela Basto, Yuji Mishima, Nazila Kamaly, Siobhan Glavey, Sufeng Zhang, Michele Moschetta, Dushanth Seevaratnam, Yong Zhang and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 280 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Archana SwamiLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Michaela R ReaganDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Pamela BastoThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
Yuji MishimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Nazila KamalyLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Siobhan GlaveyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Sufeng ZhangThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
Michele MoschettaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Dushanth SeevaratnamLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Yong ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Jinhe LiuLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Masoumeh MemarzadehDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Jun WuLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Salomon ManierDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Jinjun ShiLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;
Nicolas BertrandThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
Zhi Ning LuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Kenichi NaganoDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Harvard Medical School, Boston, MA 02115; and.
Roland BaronDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Harvard Medical School, Boston, MA 02115; and.
Antonio SaccoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Aldo M RoccaroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Omid C FarokhzadLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115;King Abdulaziz University, Jeddah, Saudi Arabia ofarokhzad@zeus.bwh.harvard.edu irene_ghobrial@dfci.harvard.edu.
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; ofarokhzad@zeus.bwh.harvard.edu irene_ghobrial@dfci.harvard.edu.
Harvard University · USMassachusetts Institute of Technology · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · US

Funding

The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2010 to 2014
$11.3M
The role of miRNA15a and 16-1 in Multiple MyelomaR01CA154648 · NCI · DANA-FARBER CANCER INST · PI GHOBRIAL, IRENE M. · 2011 to 2015
$1.8M
NF-KB and mTOR regulation in Waldenstrom MacroglobulinemiaR01FD003743 · FDA · DANA-FARBER CANCER INST · PI GHOBRIAL, IRENE M. · 2010 to 2013
$1.4M
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant CancersR00CA160350 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI SHI, JINJUN · 2013 to 2015
$724k
CIHRFDA HHS R01 FD003743NCI NIH HHS CA151884NCI NIH HHS R00 CA160350NCI NIH HHS R00CA160350NCI NIH HHS R01 CA154648NCI NIH HHS U54 CA151884PHS HHS K1A1A2048701
6 · The paper itself

Abstract

Bone is a favorable microenvironment for tumor growth and a frequent destination for metastatic cancer cells. Targeting cancers within the bone marrow remains a crucial oncologic challenge due to issues of drug availability and microenvironment-induced resistance. Herein, we engineered bone-homing polymeric nanoparticles (NPs) for spatiotemporally controlled delivery of therapeutics to bone, which diminish off-target effects and increase local drug concentrations. The NPs consist of poly(D,L-lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand). The engineered NPs were formulated by blending varying ratios of the synthesized polymers: PLGA-b-PEG and alendronate-conjugated polymer PLGA-b-PEG-Ald, which ensured long circulation and targeting capabilities, respectively. The bone-binding ability of Ald-PEG-PLGA NPs was investigated by hydroxyapatite binding assays and ex vivo imaging of adherence to bone fragments. In vivo biodistribution of fluorescently labeled NPs showed higher retention, accumulation, and bone homing of targeted Ald-PEG-PLGA NPs, compared with nontargeted PEG-PLGA NPs. A library of bortezomib-loaded NPs (bone-targeted Ald-Bort-NPs and nontargeted Bort-NPs) were developed and screened for optimal physiochemical properties, drug loading, and release profiles. Ald-Bort-NPs were tested for efficacy in mouse models of multiple myeloma (MM). Results demonstrated significantly enhanced survival and decreased tumor burden in mice pretreated with Ald-Bort-NPs versus Ald-Empty-NPs (no drug) or the free drug. We also observed that bortezomib, as a pretreatment regimen, modified the bone microenvironment and enhanced bone strength and volume. Our findings suggest that NP-based anticancer therapies with bone-targeting specificity comprise a clinically relevant method of drug delivery that can inhibit tumor progression in MM.

Indexed as

Antineoplastic AgentsBoronic AcidsDrug Delivery SystemsLactic AcidNanoparticlesPolyethylene GlycolsPolyglycolic AcidPyrazinesAlendronateAnimalsBone NeoplasmsBortezomibCell Line, TumorHeterograftsHumansMiceAlendronateAntineoplastic AgentsBoronic AcidsBortezomibLactic AcidPolyethylene GlycolsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPyrazinesalendronate-PLGA-PEGbisphosphonatebone metastasistargeting nanomedicine

Identifiers

PMID24982170
PMCPMC4104924
OpenAlexW2089220360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.